Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444529 · ClinicalTrials.gov registry record · Phase 3
A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT06444529 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 159 participants.
The verdict
NCT06444529, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.
Interventions
- DRUG Vehicle
- DRUG Apraclonidine Hydrochloride Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06444529
The ClinicalTrials.gov registry entry for NCT06444529 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT06444529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06444529 about?
NCT06444529 is a clinical study titled "A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness". The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.
What is the current status of trial NCT06444529?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2024-08-21. Estimated completion is 2025-01-08.
What interventions are being tested in trial NCT06444529?
The interventions under investigation include: Vehicle (DRUG), Apraclonidine Hydrochloride Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT06444529?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.